Best Weight Loss Programs for PCOS in 2026 (GLP-1 & Beyond)

Our picks from the programs ranked here are Mochi Health (video-visit clinical model with an insurance path for brand-name medication), Found (publishes with-insurance plan pricing, per our registry verified 2026-11-03), and Embody on price ($69/mo, medication included), with Sprout Health at $99/mo on a 12-month plan. The right pick depends on whether you want metformin discussion, insurance billing, or the lowest cash price.

In the text we could access, we could not find a published average for the first four weeks, either in women with PCOS or in the large obesity trials. We could not open the full New England Journal of Medicine papers or their figures, only the abstracts, so we will not give you a number. The published results are totals over much longer periods, such as 68 weeks in the STEP 1 semaglutide trial. Those totals cover the whole trial, including the dose-escalation period, and reflect the maintenance doses reached after it. A clinician who knows your history is the right person to ask what to expect.

Verified all-in monthly prices for the 5 programs ranked here run from $69/mo to $178/mo (prices monitored daily, last change detected November 3, 2026). Each program states its own price type, such as a plan term or promotion, and the ranked table shows that label and a verification date next to every price.

Both drugs start with a low dose. The Wegovy label starts at 0.25 mg weekly for weeks 1 to 4, then raises the dose every four weeks, with the maintenance dose beginning at week 17. The Zepbound label starts at 2.5 mg weekly for 4 weeks and says that dose is for treatment initiation and is not approved as a maintenance dosage. The Wegovy label gives the reason for gradual escalation as reducing the risk of gastrointestinal adverse reactions, and the 2023 PCOS guideline also recommends gradual dose escalation to reduce gastrointestinal adverse effects.

In STEP 1 (adults with obesity or overweight and no diabetes, not a PCOS trial), the trial abstract and the Wegovy label report an average loss of 14.9% of body weight on semaglutide over 68 weeks, compared with 2.4% on placebo. The abstract of the SURMOUNT-1 trial (also not a PCOS trial) reports that tirzepatide averaged 15.0%, 19.5% and 20.9% at 5, 10 and 15 mg over 72 weeks, compared with 3.1% on placebo, and these figures match the Zepbound label. These are long-run averages, not first-month results, and not everyone responded alike: the STEP 1 abstract reports that 86.4% of the semaglutide group lost at least 5% of body weight, versus 31.5% on placebo.

Some, but the reviews we read describe it as limited. The abstract of a 2026 meta-analysis in the European Journal of Endocrinology, covering 11 randomized trials in women with PCOS and overweight or obesity, reports that GLP-1 add-on treatment lowered BMI by 1.38 kg/m2 on average compared with controls, rated low certainty. It states the evidence was insufficient to draw conclusions on glucose, insulin, hirsutism and menstrual regularity. We did not identify a completed randomized trial of semaglutide or tirzepatide in women with PCOS in the sources we read. A 2021 meta-analysis of eight earlier trials, which used liraglutide or exenatide, reports that treatment lasted 12 weeks in six of them and 24 weeks in the other two.

The guideline says anti-obesity medications, naming liraglutide, semaglutide and orlistat, could be considered in addition to active lifestyle intervention for the management of higher weight in adults with PCOS as per general population guidelines. That is a consensus recommendation, and tirzepatide is not named. For metformin, it says metformin alone should be considered in adults with PCOS and a BMI of 25 or more for weight and metabolic outcomes, based on very low certainty evidence. It also says shared decisions about weight medication should consider side effects, and the potential need for long-term use, given the high risk of weight regain after discontinuation and the lack of long-term safety data.

Not on the labels we read: neither the Wegovy nor the Zepbound prescribing information lists PCOS as an indication. We searched the full DailyMed text of the Wegovy label (version 19, effective June 18, 2026) and the Zepbound label (version 40, effective August 28, 2026) on October 6, 2026. The Wegovy label’s indications include reducing excess body weight and maintaining weight reduction long term in adults with obesity, or adults with overweight in the presence of at least one weight-related comorbid condition, and the Zepbound label’s indications include the same wording for adults. Whether a weight medication suits a particular person with PCOS is a shared decision, which is how the 2023 guideline frames it, considering side effects, and the potential need for long-term use. If pregnancy is possible, the guideline says to ensure effective contraception is in place for women who take GLP-1 receptor agonists, because pregnancy safety data are lacking.

The sources we reviewed do not describe GLP-1 treatment as a cure for PCOS. The abstract of the 2026 meta-analysis reports a low-certainty reduction in BMI in women with PCOS and overweight or obesity and calls the evidence insufficient on glucose, insulin, hirsutism and menstrual regularity. The 2023 guideline describes lifestyle management as a core focus of PCOS management, with anti-obesity medication as something that could be considered in addition. Discuss what to expect with your own clinician.

In the two FDA labels and the 2023 guideline we found no guidance on combining metformin with a GLP-1. The 2021 meta-analysis did include arms combining a GLP-1 with metformin, using liraglutide or exenatide. The Zepbound label (version 40) does not mention metformin. The Wegovy label (version 19) mentions metformin in its drug-interaction section, which reports that no clinically significant differences in the pharmacokinetics of metformin were observed when used concomitantly with semaglutide, and in trial descriptions where some participants with type 2 diabetes were treated with metformin among other drugs; neither is guidance for PCOS. The 2023 PCOS guideline’s metformin passages cover metformin alone, with the combined oral contraceptive pill, and with clomiphene. The authors of the 2021 meta-analysis say more large-scale, high-quality randomized trials are needed. For any program, ask its clinician what they can prescribe alongside a GLP-1.